Related Experiment Video
Updated: Jul 2, 2026
06:52
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
Limb-girdle muscular dystrophies
Michela Guglieri1, Volker Straub, Kate Bushby
1Newcastle upon Tyne Muscle Centre, Institute of Human Genetics, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK.
Current Opinion in Neurology
|September 5, 2008
Summary
Recent discoveries in limb-girdle muscular dystrophies (LGMDs) reveal new genes and pathogenic pathways. This enhanced understanding promises improved diagnostics, prognostics, and novel therapeutic strategies for LGMD patients.
Area of Science:
- Neurology
- Genetics
- Muscular Dystrophy Research
Background:
- Limb-girdle muscular dystrophies (LGMDs) are a heterogeneous group of inherited neuromuscular disorders.
- Characterized by progressive muscle weakness primarily affecting the shoulders and hips.
- Genetic and clinical variability presents diagnostic and therapeutic challenges.
Purpose of the Study:
- To provide an updated analysis of current knowledge on limb-girdle muscular dystrophies.
- To review recent genetic discoveries and pathogenetic mechanisms.
- To highlight implications for diagnostics, prognostics, and therapeutics.
Main Methods:
- Comprehensive literature review of recent studies on LGMD.
- Analysis of newly discovered LGMD genes and associated pathogenetic pathways.
- Synthesis of findings related to alpha-dystroglycan, calpainopathies, dysferlinopathies, and titinopathies.
Main Results:
- Discovery of new LGMD genes has expanded the known genetic heterogeneity.
- Identification of shared pathogenetic pathways between LGMD and congenital muscular dystrophies, particularly involving alpha-dystroglycan.
- Emerging insights into calpainopathies, dysferlinopathies, and titinopathies offer new therapeutic avenues.
Conclusions:
- Increased understanding of LGMD genetics and pathogenesis will refine diagnostic and prognostic accuracy.
- New findings pave the way for novel therapeutic strategies and clinical trials.
- Global patient registries are crucial for advancing natural history knowledge and translational research.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Cross-bridge Cycle
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...